There are 3163 resources available
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13
1998P - Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC)
Presenter: Dingwei Ye
Session: Poster session 13
1999P - Expression heterogeneity of ADC-related targets between primary tumors and metastatic lymph nodes in advanced urothelial cancers
Presenter: Xingliang Tan
Session: Poster session 13
2001P - Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study
Presenter: Florence Joly Lobbedez
Session: Poster session 13
2002P - Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study
Presenter: Luzhe Yan
Session: Poster session 13